AnaptysBio, Inc. Common Stock
Symbol: ANAB (NASDAQ)
Company Description:
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Today's Open: $31.58
- Today's High: $32.999
- Today's Low: $30.57
- Today's Volume: 353.61K
- Yesterday Close: $31.34
- Yesterday High: $32.15
- Yesterday Low: $30
- Yesterday Volume: 808.48K
- Last Min Volume: 29
- Last Min High: $30.57
- Last Min Low: $30.57
- Last Min VWAP: $30.57
- Name: AnaptysBio, Inc. Common Stock
- Website: https://www.anaptysbio.com
- Listed Date: 2017-01-26
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001370053
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $865.48M
- Round Lot: 100
- Outstanding Shares: 27.97M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-10-01 | 4 | View |
2025-09-30 | 144 | View |
2025-09-29 | 8-K | View |
2025-09-23 | SCHEDULE 13G | View |
2025-09-17 | 4 | View |
2025-08-12 | 4 | View |
2025-08-08 | 144 | View |
2025-08-07 | SCHEDULE 13G/A | View |
2025-08-06 | S-8 | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-08-05 | SCHEDULE 13G | View |
2025-07-29 | SCHEDULE 13G | View |
2025-07-03 | 4 | View |
2025-07-02 | 144 | View |
2025-06-20 | 4 | View |
2025-06-20 | 4 | View |
2025-06-18 | 144 | View |
2025-06-18 | 144 | View |
2025-06-17 | 4 | View |